Quantcast

Latest Boehringer Ingelheim Stories

2014-09-18 08:28:26

- Boehringer Ingelheim obtains exclusive global rights for development and commercialization of CureVac's investigational therapeutic cancer vaccine CV9202 INGELHEIM and TUBINGEN, Germany, and RIDGEFIELD, Conn., Sept. 18, 2014 /PRNewswire/ -- Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, today jointly announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel...

2014-09-15 23:06:32

The Nation’s Premier Annual Physical Activity and Hispanic Family Health Celebration Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Are Title Sponsor New York, NY (PRWEB) September 15, 2014 On Sunday, September 21, 2014, the Hispanic Federation will present its eighth annual family health and fitness fair ¡Vive tu vida! Get Up! Get Moving!® at Carnaval de la Cultura Latina. The event promotes Hispanic family physical activity and good nutrition for...

2014-09-10 12:24:27

RIDGEFIELD, Conn., Sept. 10, 2014 /PRNewswire/ -- In support of Pulmonary Fibrosis Awareness Month, Boehringer Ingelheim Pharmaceuticals, Inc., announces the airing of Every Breath Counts: Idiopathic Pulmonary Fibrosis -- a documentary supported by the company and created in collaboration with the Pulmonary Fibrosis Foundation and the Coalition for Pulmonary Fibrosis in an effort to increase awareness and understanding of idiopathic pulmonary fibrosis (IPF) among the general public....

2014-09-09 08:32:06

For U.S. Media Only RIDGEFIELD, Conn., Sept. 9, 2014 /PRNewswire/ -- A pre-specified, pooled subgroup sensitivity analysis from the two identically designed Phase III INPULSIS(TM) trials, presented today at the European Respiratory Society International Congress (ERS) evaluated the impact of the investigational drug nintedanib on reducing the decline in lung function, as measured by annual rate of decline in forced vital capacity (FVC), in patients with idiopathic pulmonary fibrosis (IPF)...

2014-09-08 12:30:18

Additionally, data from the WISDOM trial on stepwise withdrawal of ICS in COPD was also presented at ERS and simultaneously published in the New England Journal of Medicine RIDGEFIELD, Conn., Sept. 8, 2014 /PRNewswire/ -- Boehringer Ingelheim today presented the first data from the pivotal Phase III TONADO(TM) 1&2 studies (NCT01431274/NCT01431287) for the fixed-dose combination (FDC) of tiotropium plus olodaterol delivered via the Respimat(®) inhaler in patients with moderate to...

2014-09-08 12:29:32

For U.S. Media Only RIDGEFIELD, Conn., Sept. 8, 2014 /PRNewswire/ -- Boehringer Ingelheim today presented new data from the company's Phase III trial program (UniTinA-asthma(®)) evaluating tiotropium in asthma, including the first study assessing the efficacy and safety of tiotropium in adolescent patients with symptomatic asthma. These data were unveiled during an oral session at the European Respiratory Society (ERS) International Congress 2014 in Munich, Germany. Tiotropium is...

2014-09-05 08:24:07

BLACKSBURG, Va., Sept. 5, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Keith Canada, Ph.D., as Vice President, UltraVector(®) Division, effective September 15. He will report to Chief Operating Officer Krish Krishnan. Dr. Canada's recruitment coincides with the recent introduction of the BeyondBio((TM)) portal, which further expands the accessibility of Intrexon's UltraVector(® )platform to its diverse...

2014-09-02 23:06:21

The Nation’s Premier Annual Physical Activity and Hispanic Family Health Celebration Dallas, TX (PRWEB) September 02, 2014 On Saturday, September 6, 2014, The Concilio will present its eighth annual family health and fitness fair ¡Vive tu vida! Get Up! Get Moving!®. This event promotes Hispanic family physical activity and good nutrition for better health and wellness for people of all ages and all sizes. The event, which is free and open to the public, will be held at Kiest...

2014-09-02 08:30:31

Patients at higher risk of kidney problems due to existing diabetes were also evaluated for the effects of warfarin on kidney function RIDGEFIELD, Conn., Sept. 2, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a new post-hoc sub-analysis of the pivotal phase III RE-LY® trial assessing renal function change in patients with non-valvular atrial fibrillation (NVAF) treated with Pradaxa® (dabigatran etexilate mesylate) compared to warfarin. The...

2014-08-26 12:27:14

Sales of the LABA/LAMA Combination Drug Class are Expected to Grow Significantly Over the Next Six Months, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 26, 2014 /PRNewswire/ -- Decision Resources Group finds that two-thirds of surveyed pulmonologists indicate that Boehringer Ingelheim's Spiriva is the agent most likely to be replaced by GlaxoSmithKline/Theravance's first-in-class LABA/LAMA combination Anoro Ellipta. To date, surveyed physicians reported that, of...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.